Therapeutic Advances in Endocrinology and Metabolism最新文献

{"title":"Understanding the burden of weekly somatrogon injections compared with daily somatropin injections in children with growth hormone deficiency: a plain language summary of publication.","authors":"Aristides K Maniatis, Mauri Carakushansky, Sonya Galcheva, Gnanagurudasan Prakasam, Larry A Fox, Adriana Dankovcikova, Jane Loftus, Andrew A Palladino, Maria de Los Angeles Resa, Carrie Turich Taylor, Mehul T Dattani, Jan Lebl","doi":"10.1177/20420188241274363","DOIUrl":"https://doi.org/10.1177/20420188241274363","url":null,"abstract":"<p><p>• For children with growth <b>hormone</b> deficiency, once-weekly <b>somatrogon</b> injections were less of a burden than once-daily <b>somatropin</b> injections. • The safety of weekly <b>somatrogon</b> was similar to that of daily <b>somatropin</b>. • Compared with daily <b>somatropin</b> injections, children with growth <b>hormone</b> deficiency may be less likely to miss weekly <b>somatrogon</b> injections.  ○ This is because weekly <b>somatrogon</b> injections were less of a burden and were less likely to interfere with daily activities compared with daily <b>somatropin</b> injections. The purpose of this plain language summary is to help you to understand the findings from recent research. • <b>Somatrogon</b> is used to treat the condition under study that is discussed in this summary. Approval varies by country; please check with your local provider for more details. • The results of this study may differ from those of other studies. Health professionals should make treatment decisions based on all available evidence and not on the results of a single study. <b>This original scientific article on which this summary is based was published in the <i>Journal of the Endocrine Society</i> and can be accessed for free at: https://academic.oup.com/jes/article/6/10/bvac117/6695276. The details of the original article are as follows:</b> <i>Aristides K. Maniatis, Mauri Carakushansky, Sonya Galcheva, Gnanagurudasan Prakasam, Larry A. Fox, Adriana Dankovcikova, Jane Loftus, Andrew A. Palladino, Maria de los Angeles Resa, Carrie Turich Taylor, Mehul T. Dattani, Jan Lebl</i>. Treatment burden of weekly <b>somatrogon</b> versus daily <b>somatropin</b> in children with growth <b>hormone</b> deficiency: a randomized study. <i>J Endocr Soc</i> 2022; 6(10): bvac117. DOI: 10.1210/jendso/bvac117.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing quality of life in traditional face-to-face visits with a hybrid approach of telemedicine with in-person follow-ups in recent users of advanced closed-loop systems: a randomized controlled clinical trial in patients with type 1 diabetes.","authors":"Lía Nattero-Chávez, Esther de La Calle, Edurne Lecumberri-Pascual, Ane Bayona Cebada, Teresa Ruiz Gracia, Alejandra Quintero Tobar, Mar Lorenzo Moñino, Cristina Sánchez Rodríguez, Ana Izquierdo, Héctor F Escobar-Morreale, Manuel Luque-Ramírez","doi":"10.1177/20420188241288789","DOIUrl":"10.1177/20420188241288789","url":null,"abstract":"<p><strong>Background: </strong>Our objective was to assess the effect of a hybrid telemedicine approach, in conjunction with face-to-face follow-up, on the quality of life in recent users of an advanced hybrid closed-loop (AHCL) system.</p><p><strong>Methods: </strong>A 1-year open randomized (1:1) clinical trial (ClinicalTrials.gov ID NCT04900636). Participants with type 1 diabetes (T1D) recent users of an AHCL system (Minimed^® 780G) for at least 2-6 months, and ⩾18 years old were eligible. The primary outcome was the change in quality of life measured by the Type 1 Diabetes Life (ViDa1) Questionnaire from baseline to 12 months of hybrid telemedicine plus face-to-face follow-up compared to standard clinical practice. Additionally, impacts on A_1c levels, glucose metrics, advert events, and safety outcomes were assessed.</p><p><strong>Results: </strong>Between January and December 2021, 46 participants were randomly assigned in a 1:1 ratio to either the hybrid telemedicine group (<i>n</i> = 23) or the control group (<i>n</i> = 23); 45 participants completed the study, with only 1 from the control group withdrawing before visit 3. At baseline, mean age was 37 ± 15 years and A_1c was 6.9 ± 0.5%. After 12 months, no statistically significant differences in ViDa1 scores between groups were observed. Despite reducing in-person visits in the hybrid follow-up arm, there were no increases in adverse events. Overall, A_1c levels significantly decreased from 6.9 ± 0.5% at baseline to 6.7 ± 0.5% after 12 months (<i>P</i> = 0.006) without differences between treatment arms, accompanied by reductions in glycemic variability and time below the target range.</p><p><strong>Conclusion: </strong>Our study suggests that there were no significant differences in ViDa1 scores between the two groups at the end of the follow-up. However, among adult patients with T1D who recently adopted an AHCL system, satisfactory glycemic control can be attained through a hybrid follow-up approach, reducing face-to-face visits, without increasing technical complications.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measurement of salivary thyroid hormones using the LC-MS/MS technique in a clinical setting.","authors":"Nadia Sawicka-Gutaj, Piotr Glinicki, Kacper Nijakowski, Barbara Bromińska, Magdalena Ostrowska, Alicja Szatko, Zuzanna Sobol, Konrad Kowalski, Paweł Wilk, Wojciech Zgliczyński, Marek Ruchała","doi":"10.1177/20420188241277414","DOIUrl":"10.1177/20420188241277414","url":null,"abstract":"<p><strong>Background: </strong>Saliva could be an attractive alternative to blood for assessing thyroid hormonal function.</p><p><strong>Objectives: </strong>Our goal was to determine if the levels of thyroid hormones in saliva can accurately reflect a person's thyroid status and if they consistently correlate with the levels of the same hormones in the blood.</p><p><strong>Design: </strong>We conducted a cross-sectional study.</p><p><strong>Methods: </strong>We enrolled a total of 109 participants with different thyroid conditions. We measured TSH (Thyroid-Stimulating Hormone), free T3 (fT3), and free T4 (fT4) in the blood using two different immunoassay methods: electrochemiluminescence immunoassay (ECLIA) and chemiluminescence immunoassay (CLIA). Saliva samples were collected using Salivette^® tubes, and then we analyzed the levels of thyroid hormones in the saliva using liquid chromatography with tandem mass spectrometry (LC-MS/MS).</p><p><strong>Results: </strong>Comparing salivary and serum levels of thyroid hormones, we observed significantly lower fT4 and higher fT3 levels in saliva (<i>p</i> < 0.001), regardless of the measurement method. We also found that salivary fT3 and fT4 levels were positively correlated in the entire group of participants (<i>p</i> < 0.001, <i>R</i> 0.575), as well as in those with TSH values within the normal reference range (<i>p</i> < 0.001, <i>R</i> 0.570). We further divided participants based on their TSH reference intervals and assessed the correlations between serum and salivary thyroid hormones within these groups. We also discovered that taking exogenous levothyroxine influenced the correlations between serum and salivary thyroid hormones. Thyroid antibodies did not have a significant impact on the levels of thyroid hormones in both serum and saliva.</p><p><strong>Conclusion: </strong>This study demonstrates that salivary thyroid hormones can partially reflect the levels of these hormones in the blood. Saliva may be a useful tool in a clinical setting for patients with thyroid antibodies, but it may not be as effective for those who are taking levothyroxine as a treatment.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11505444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amputation versus circular external fixation in the treatment of diabetic foot with osteomyelitis: a cost and quality-of-life analysis.","authors":"Laia López Capdevilla, Alejandro Santamaría Fumas, José Miguel Sales Pérez, Alejandro Domínguez Sevilla, Julio Del Corral Cuervo, Carlos Varela-Quintana, María Rabanal Rubio, Pablo Roza Miguel","doi":"10.1177/20420188241271795","DOIUrl":"10.1177/20420188241271795","url":null,"abstract":"<p><strong>Background: </strong>Charcot foot is a severe complication of diabetes mellitus. Amputation is associated with 5-year mortality rates as high as 70%, and the overall treatment cost for diabetic foot surpasses that of conditions such as cancer or depression.</p><p><strong>Objectives: </strong>To compare clinical, quality-of-life, and cost outcomes related to Charcot foot management through two distinct treatments: amputation and resection with stabilization using circular external fixation (CEF).</p><p><strong>Methods: </strong>This retrospective study included all adult patients treated at our unit between 2008 and 2022 for acute diabetic foot with infected ulcers. The allocation to treatment groups was based on the timing of patient enrollment. We gathered anthropometric, diagnostic, and surgical data, documenting individualized costs for preoperative, postoperative, and rehabilitation phases. Health status was assessed using the EQ-5D-3L questionnaire, and recorded data included mortality.</p><p><strong>Results: </strong>A total of 31 patients (18 amputations; 13 CEF) were included. Amputees exhibited significantly higher mortality compared to those with a CEF (44.8% vs 7.7%, <i>p</i> = 0.045). The estimated 3-year survival was 60.8% for amputees and 90% for the CEF group (log-rank test, <i>p</i> = 0.096). In terms of quality of life (EQ-5D-3L), amputees reported a reduction of 14.67 points while CEF patients reported an increase of 40.39 points (<i>p</i> < 0.001). The EQ-5D-3L index improved by 1.8 points for amputees, as compared with 62.3 points in the CEF group (<i>p</i> < 0.001). The total mean cost of managing an amputated patient was €222,864, practically identical to the €224,438 incurred in the CEF group (<i>p</i> = 0.767). No statistically significant differences were found in the time distribution of costs. However, some specific expense items demonstrated statistical significance.</p><p><strong>Conclusion: </strong>In treating infected diabetic foot ulcers, external fixation leads to a better quality of life compared to amputation. There's also a trend suggesting higher survival rates with external fixation, and both approaches have similar costs.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noninsulin antidiabetic prescription patterns in Colombia: a cross-sectional study.","authors":"Jorge Enrique Machado-Alba, Andrés Gaviria-Mendoza, Manuel Enrique Machado-Duque, Luis Fernando Valladales-Restrepo, Andrés Alvarado-Segovia","doi":"10.1177/20420188241271806","DOIUrl":"10.1177/20420188241271806","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of type 2 diabetes mellitus (T2DM) continues to increase; the clinical practice guidelines continue to modify the recommendations for its treatment.</p><p><strong>Objective: </strong>The aim was to determine the prescription patterns of noninsulin antidiabetics in a group of patients from Colombia.</p><p><strong>Design: </strong>Cross-sectional study.</p><p><strong>Methods: </strong>The use of noninsulin antidiabetic drugs based on a population database of patients under treatment in 2022. Comorbidities were identified, including total numbers, proportions, and defined daily doses of each antidiabetic agent per 1000 inhabitants/day (DHD).</p><p><strong>Results: </strong>A total of 155,381 patients with T2DM were identified, with a mean age of 67.1 ± 12.0 years. The most widely used antidiabetics according to DHD were metformin (9.46 DHD), empagliflozin (5.3), sitagliptin (2.8), linagliptin (2.4), and dapagliflozin (2.3), mainly in combination therapy (55.5%), most often two (31.2% of patients) or three antidiabetics (22.4% of patients). The most frequent cardiovascular comorbidities were hypertension (67.6%), chronic kidney disease (6.3%), and coronary ischemic heart disease (2.5%), treated with angiotensin 2 receptor antagonists, followed by diuretics, calcium antagonists, and β-blockers.</p><p><strong>Conclusion: </strong>This group of patients with T2DM has been treated mainly with metformin alone or in combination with other antidiabetic drugs, but despite the changes in treatment in recent years, a significant number of patients with concomitant cardiovascular conditions are not receiving appropriate antidiabetic agents. Sodium-glucose type 2 cotransporter or glucagon-like peptide-1 receptor agonists may offer additional benefits with reduced cardiovascular risk.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excessive or sustained endoplasmic reticulum stress: one of the culprits of adipocyte dysfunction in obesity.","authors":"Yu Jiang, Jia-Qi Guo, Ya Wu, Peng Zheng, Shao-Fan Wang, Meng-Chen Yang, Gen-Shan Ma, Yu-Yu Yao","doi":"10.1177/20420188241282707","DOIUrl":"https://doi.org/10.1177/20420188241282707","url":null,"abstract":"<p><p>As the prevalence of obesity continues to rise globally, the research on adipocytes has attracted more and more attention. In the presence of nutrient overload, adipocytes are exposed to pressures such as hypoxia, inflammation, mechanical stress, metabolite, and oxidative stress that can lead to organelle dysfunction. Endoplasmic reticulum (ER) is a vital organelle for sensing cellular pressure, and its homeostasis is essential for maintaining adipocyte function. Under conditions of excess nutrition, ER stress (ERS) will be triggered by the gathering of abnormally folded proteins in the ER lumen, resulting in the activation of a signaling response known as the unfolded protein responses (UPRs), which is a response system to relieve ERS and restore ER homeostasis. However, if the UPRs fail to rescue ER homeostasis, ERS will activate pathways to damage cells. Studies have shown a role for disturbed activation of adipocyte ERS in the pathophysiology of obesity and its complications. Prolonged or excessive ERS in adipocytes can aggravate lipolysis, insulin resistance, and apoptosis and affect the bioactive molecule production. In addition, ERS also impacts the expression of some important genes. In view of the fact that ERS influences adipocyte function through various mechanisms, targeting ERS may be a viable strategy to treat obesity. This article summarizes the effects of ERS on adipocytes during obesity.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth hormone treatment in children with Prader-Willi syndrome: safety and effectiveness data from the PATRO Children study.","authors":"Constanze Lämmer, Philippe Backeljauw, Maite Tauber, Shankar Kanumakala, Sandro Loche, Karl Otfried Schwab, Roland Pfäffle, Charlotte Höybye, Elena Lundberg, Jovanna Dahlgren, Anna E Ek, Tadej Battelino, Berit Kriström, Altaher Esmael, Markus Zabransky","doi":"10.1177/20420188241264343","DOIUrl":"10.1177/20420188241264343","url":null,"abstract":"<p><strong>Background: </strong>Recombinant human growth hormone (rhGH, somatropin) therapy is approved in children with Prader-Willi syndrome (PWS).</p><p><strong>Objectives: </strong>To report safety and effectiveness data for children with PWS treated with biosimilar rhGH (Omnitrope^®, Sandoz) in the PAtients TReated with Omnitrope (PATRO) Children study.</p><p><strong>Design: </strong>PATRO Children was a multicenter, non-interventional, postmarketing surveillance study.</p><p><strong>Methods: </strong>Children with PWS received Omnitrope according to standard clinical practice. Adverse events (AEs) were monitored for the duration of Omnitrope treatment. Effectiveness outcomes were also assessed, including height standard deviation (SD) scores (HSDS).</p><p><strong>Results: </strong>As of July 2020 (study completion), 235 patients with PWS had been enrolled. At baseline, 95.7% (<i>n</i> = 225) of patients were prepubertal and 86.4% (<i>n</i> = 203) were rhGH treatment-naïve. At analysis, the median (range) treatment duration in the study was 56.8 (2.9-155.8) months. AEs were reported in 192 patients (81.7%) and were suspected as treatment-related in 39 patients (16.6%). Serious AEs (SAEs) were reported in 96 patients (40.9%) and were suspected as treatment-related in 22 patients (9.4%). The most frequent treatment-related SAEs were sleep apnea syndrome (<i>n</i> = 11; 4.7%), tonsillar hypertrophy (<i>n</i> = 4; 1.7%), and adenoidal hypertrophy (<i>n</i> = 4; 1.7%). Development of scoliosis was considered treatment-related in two patients; development of impaired glucose tolerance in one patient and type 2 diabetes mellitus in another patient were considered treatment-related. Effectiveness outcomes were primarily assessed in 153 patients who completed 3 years of treatment. Among the 151 prepubertal patients (135 treatment-naïve), mean (SD) change from baseline in HSDS after 3 years was +1.50 (1.07) across all patients and +1.57 (1.07) for treatment-naïve patients.</p><p><strong>Conclusion: </strong>These data suggest that biosimilar rhGH is well tolerated and effective in patients with PWS managed in real-life clinical practice. Patients with PWS should continue to be closely monitored for well-known safety issues (including respiratory, sleep, and glucose metabolism disorders, and scoliosis) during rhGH treatment.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific impact of <i>GCKR</i> rs1260326 polymorphism on metabolic traits in an older Japanese population: the Bunkyo Health Study.","authors":"Shota Sakamoto, Saori Kakehi, Abulaiti Abudurezake, Hideyoshi Kaga, Yuki Someya, Hiroki Tabata, Yasuyo Yoshizawa, Hitoshi Naito, Tsubasa Tajima, Naoaki Ito, Ryuzo Kawamori, Hirotaka Watada, Yoshifumi Tamura","doi":"10.1177/20420188241280540","DOIUrl":"https://doi.org/10.1177/20420188241280540","url":null,"abstract":"<p><strong>Background: </strong>Metabolic syndrome involves health problems influenced by aging and genetics. The glucokinase regulatory protein (<i>GCKR</i>) rs1260326 polymorphism (Leu446) is associated with metabolic traits. This study explores the impact of the GCKR rs1260326 polymorphism on metabolic traits in older Japanese with focusing on sex-specific differences.</p><p><strong>Methods: </strong>This cross-sectional study from the Bunkyo Health Study in Tokyo, Japan, examined 883 participants aged 65-84 years. Participants were excluded with diabetes, or on drug treatment for diabetes or dyslipidemia. The <i>GCKR</i> P446L polymorphism was analyzed and compared their characteristics of physical activity, dietary intake, body composition, and metabolic parameters.</p><p><strong>Results: </strong>Study participants with <i>GCKR</i> rs1260326 genotypes (C/C 20.7%, C/T 47.6%, T/T 31.7%) had a median age of 72 years, and 60.4% were women. Men with the T/T genotype, as compared to the C/C genotype, had a lower body weight, body mass index (BMI), and skeletal mass index. This genotype also associated with lower fasting insulin, homeostasis model assessment of insulin resistance index (HOMA-IR), and higher Matsuda index, but not after adjustment for age, BMI, and physical activity. In contrast, women with the T/T genotype, compared to the C/C genotype, showed higher C-reactive protein, fibroblast growth factor 21, and Matsuda index. They also had lower fasting insulin, insulin area under the curve, and HOMA-IR; with these associations being independent of age, BMI, and physical activity.</p><p><strong>Conclusion: </strong>The <i>GCKR</i> rs1260326 genotype-affected metabolic traits differentially by sex in older Japanese. This highlights the need to consider sex differences in <i>GCKR</i>-related metabolic outcomes.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11437585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic-associated fatty liver disease and pregnancy complications: new challenges and clinical perspectives.","authors":"Yang Zhang, Yifan Bu, Rui Zhao, Cheng Han","doi":"10.1177/20420188241274350","DOIUrl":"10.1177/20420188241274350","url":null,"abstract":"<p><p>The term metabolic-associated fatty liver disease (MAFLD), with a global prevalence estimated at 38.77%, has gradually replaced the traditional concept of non-alcoholic fatty liver disease (NAFLD). Compared to the general population, the incidence of MAFLD is notably higher among pregnant women, posing potential risks to both maternal and neonatal health. This review summarizes the latest research on MAFLD, focusing on its association with pregnancy complications. Additionally, it provides a comparative analysis with previous studies on NAFLD, presenting a comprehensive perspective for clinical management. Findings suggest that pregnant women with MAFLD face a higher risk of gestational hypertension and cesarean delivery compared to those with NAFLD, while the risk for gestational diabetes mellitus remains similar between the two conditions. Additionally, MAFLD is associated with an increased likelihood of delivering large-for-gestational-age infants and heightened risks of preterm birth and low birth weight. Current treatment strategies for MAFLD focus on lifestyle modifications, such as dietary adjustments and increased physical activity. However, there is an urgent need for the development of safe and effective pharmacological treatments, particularly tailored toward pregnant women. Future research should delve deeper into the causal relationships between MAFLD and pregnancy complications and explore optimal therapeutic approaches to improve outcomes for mothers and their infants.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analyzing and evaluating the prevalence and metabolic profile of lean NAFLD compared to obese NAFLD: a systemic review and meta-analysis.","authors":"Hareer Fatima, Hussain Sohail Rangwala, Muhammad Saqlain Mustafa, Muhammad Ashir Shafique, Syed Raza Abbas, Burhanuddin Sohail Rangwala","doi":"10.1177/20420188241274310","DOIUrl":"10.1177/20420188241274310","url":null,"abstract":"<p><strong>Background: </strong>Non-alcoholic fatty liver disease (NAFLD) is a common liver condition affecting 25%-40% of the worldwide population. NAFLD is traditionally related to obesity and metabolic disorders. NAFLD can also affect non-obese individuals, termed \"lean NAFLD\" (LN), who exhibit a paradoxical combination of physical leanness and metabolic obesity. Factors contributing to LN remain unclear, necessitating further research. This analysis aims to understand LN's prevalence and metabolic characteristics compared to obese NAFLD (ON) populations.</p><p><strong>Methods: </strong>This meta-analysis searched various databases until August 1, 2023. Inclusion criteria involved observational studies comparing LN with overweight/obese NAFLD. Data extraction included baseline characteristics, disease occurrence, metabolic profile, and clinical parameters-statistical analysis employed calculating risk ratios (RR) and standard mean differences.</p><p><strong>Results: </strong>Twenty-five studies were analyzed. LN is associated with lower prevalence in both NAFLD (RR 0.27, 95% confidence interval (CI) 0.14-0.52, <i>p</i> = <0.0001) and total (RR 0.27, 95% CI 0.15-0.51, <i>p</i> < 0.0001) population. LN had lower diabetes mellitus (RR 0.78, 95% CI 0.71-0.87, <i>p</i> < 0.00001), dyslipidemia (RR 0.87, 95% CI 0.79-0.95, <i>p</i> = 0.002), hypertension (RR 0.80, 95% CI 0.74-0.87, <i>p</i> < 0.00001), and metabolic syndrome (RR 0.45, 95% CI 0.31-0.64, <i>p</i> < 0.00001) compared to those with ON. The LN group's lipid profile, blood pressure, and other clinical parameters were favorable compared to ON.</p><p><strong>Conclusion: </strong>The prevalence of NAFLD among lean and non-lean individuals varies by region. Our analysis revealed that LN is associated with lower metabolic diseases, fasting blood sugar, blood pressure, and a more favorable lipid profile compared to ON.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142133833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}